'Experts' Too Often Feeding From Industry Troughs  

Related News

• Congress to Probe 'Misleading' Drug Ads

  May 8, 08 3:10 AM CDT
  A congressional panel will examine three ad campaigns as part of a move to tighten regulations on drug companies' direct-to-consumer marketing, the Wall Street Journal reports. The committee will focus on ads for cholesterol drugs Vytorin and Lipitor, and anemia drug Procrit, which has been promoted as an anti-fatigue drug despite FDA demands not to do so. More »

• Prices Jump for Top Drugs

  Feb 21, 08 4:45 AM CST
  Drug companies have slapped a series of huge price hikes on some prescription drugs ahead of drug patent expirations, the Wall Street Journal reports. GlaxoSmithKline has raised the price of antidepressant Wellbutrin 44.5%, while Sanofi-Aventis hiked Ambien's price 70%. Wholesale prices for the top 50 drugs increased an average of nearly 8% last year. More »

• Cancer Still Winning War ...on Cancer

  Dec 2, 07 5:35 PM CST
  Nixon declared war on cancer in '71, but $69 billion in funding and claims of near victory are yet to slow it down, the Boston Globe reports. No one knows what makes it spread—and trigger 90% of cancer deaths—and a drop in deaths is due to lifestyle changes and early diagnosis, not better drugs. Yet one expert claims that progress is being made, quietly, behind closed doors. More »

• Psych Drugs Drove Kid Crazy

  May 18, 07 9:44 PM CDT
  The careless prescription of anti-psychotic drugs, often by psychiatrists who draw pay checks from the companies who make them, has drawn attention in the New York Times recently. Now Ann Bauer, writing in Salon, draws an intimate portrait of the effects of such carelessness on one autistic teenager, who turned from shy chess nerd to psychotic bruiser. More »

• FDA Given New Muscle To Monitor Drugs

  May 10, 07 5:41 AM CDT
  The Food and Drug Administration would be given sweeping new powers to order drug recalls, regulate advertising and mandate changes in labels under a bill passed by the Senate yesterday. The bill signals a fundamental shift in the FDA's role, the New York Times reports, requiring the agency to track drugs after, as well as before, approval. More »